Cargando…
Review of teriflunomide and its potential in the treatment of multiple sclerosis
In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, al...
Autores principales: | Warnke, Clemens, Meyer zu Hörste, Gerd, Hartung, Hans-Peter, Stüve, Olaf, Kieseier, Bernd C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699658/ https://www.ncbi.nlm.nih.gov/pubmed/19557143 |
Ejemplares similares
-
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011) -
Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis
por: Kieseier, Bernd C., et al.
Publicado: (2014) -
Quinpramine Ameliorates Rat Experimental Autoimmune Neuritis and Redistributes MHC Class II Molecules
por: Meyer zu Hörste, Gerd, et al.
Publicado: (2011) -
Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling
por: Szepanowski, Fabian, et al.
Publicado: (2016)